Masaoka T
Center for Adult Diseases, Osaka.
Gan To Kagaku Ryoho. 1989 Nov;16(11):3543-9.
Results from phase I/II studies of Granulocyte-colony stimulating factor (G-CSF) for bone marrow transplantation were reported. G-CSF in 200-800 micrograms/m2 was administered from day 3 or 5 daily for 14 days. A very rapid recovery of granulocytes was observed in most cases. Stem cell exhaustion was considered not serious. Stimulation on myeloid leukemic cells was observed in vitro tests, but relapse was observed in only 2 out of 17 myeloid leukemia patients. There was no marked difference in the grade and incidence of GVHD from historical control patients. As side effects, 3 cases of bone pain and 2 of skin rash were observed. All these symptoms were slight, reversible and tolerated for further administration. As a whole, courses of BMT with G-CSF seemed very smooth and uneventful with very rapid and steady recovery of granulocytes. G-CSF seemed promising for bone marrow transplantation in which the severe granulocytopenic stage is inevitable and normal stem cells without contact with cytostatic agents are procured.
报告了粒细胞集落刺激因子(G-CSF)用于骨髓移植的I/II期研究结果。从第3天或第5天开始,每天给予200-800微克/平方米的G-CSF,持续14天。大多数病例中观察到粒细胞非常迅速地恢复。干细胞耗竭被认为不严重。体外试验中观察到对髓系白血病细胞有刺激作用,但17例髓系白血病患者中仅2例出现复发。与历史对照患者相比,移植物抗宿主病(GVHD)的分级和发生率没有显著差异。作为副作用,观察到3例骨痛和2例皮疹。所有这些症状都很轻微,可逆且可耐受进一步给药。总体而言,使用G-CSF的骨髓移植过程似乎非常顺利和平稳,粒细胞恢复非常迅速且稳定。G-CSF对于骨髓移植似乎很有前景,在骨髓移植中,严重粒细胞减少阶段不可避免,且要获取未接触细胞抑制剂的正常干细胞。